vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Oportun Financial Corp (OPRT). Click either name above to swap in a different company.
Oportun Financial Corp is the larger business by last-quarter revenue ($247.7M vs $196.0M, roughly 1.3× Axsome Therapeutics, Inc.). Oportun Financial Corp runs the higher net margin — 1.4% vs -14.6%, a 15.9% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -1.3%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -0.5%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Oportun Financial Corp is a US-based fintech firm that provides accessible, responsible financial services including personal loans, credit cards, and savings products to underserved low-to-moderate income consumers, many with limited or no credit history, leveraging proprietary AI underwriting to deliver fair terms while mitigating operational risk.
AXSM vs OPRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $247.7M |
| Net Profit | $-28.6M | $3.4M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | 2.6% |
| Net Margin | -14.6% | 1.4% |
| Revenue YoY | 65.0% | -1.3% |
| Net Profit YoY | 61.9% | -61.0% |
| EPS (diluted) | $-0.55 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $247.7M | ||
| Q3 25 | $171.0M | $238.7M | ||
| Q2 25 | $150.0M | $234.3M | ||
| Q1 25 | $121.5M | $235.9M | ||
| Q4 24 | $118.8M | $250.9M | ||
| Q3 24 | $104.8M | $250.0M | ||
| Q2 24 | $87.2M | $250.4M | ||
| Q1 24 | $75.0M | $250.5M |
| Q4 25 | $-28.6M | $3.4M | ||
| Q3 25 | $-47.2M | $5.2M | ||
| Q2 25 | $-48.0M | $6.9M | ||
| Q1 25 | $-59.4M | $9.8M | ||
| Q4 24 | $-74.9M | $8.7M | ||
| Q3 24 | $-64.6M | $-30.0M | ||
| Q2 24 | $-79.3M | $-31.0M | ||
| Q1 24 | $-68.4M | $-26.4M |
| Q4 25 | -13.8% | 2.6% | ||
| Q3 25 | -27.0% | 6.0% | ||
| Q2 25 | -24.5% | 4.3% | ||
| Q1 25 | -46.9% | 5.6% | ||
| Q4 24 | -61.1% | 89.6% | ||
| Q3 24 | -59.8% | -15.8% | ||
| Q2 24 | -89.5% | -19.6% | ||
| Q1 24 | -89.7% | -12.2% |
| Q4 25 | -14.6% | 1.4% | ||
| Q3 25 | -27.6% | 2.2% | ||
| Q2 25 | -32.0% | 2.9% | ||
| Q1 25 | -48.9% | 4.1% | ||
| Q4 24 | -63.1% | 200.1% | ||
| Q3 24 | -61.7% | -12.0% | ||
| Q2 24 | -91.0% | -12.4% | ||
| Q1 24 | -91.1% | -10.6% |
| Q4 25 | $-0.55 | $0.07 | ||
| Q3 25 | $-0.94 | $0.11 | ||
| Q2 25 | $-0.97 | $0.14 | ||
| Q1 25 | $-1.22 | $0.21 | ||
| Q4 24 | $-1.54 | $0.26 | ||
| Q3 24 | $-1.34 | $-0.75 | ||
| Q2 24 | $-1.67 | $-0.78 | ||
| Q1 24 | $-1.44 | $-0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $105.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $390.1M |
| Total Assets | $689.8M | $3.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $105.5M | ||
| Q3 25 | $325.3M | $104.6M | ||
| Q2 25 | $303.0M | $96.8M | ||
| Q1 25 | $300.9M | $78.5M | ||
| Q4 24 | $315.4M | $60.0M | ||
| Q3 24 | $327.3M | $71.8M | ||
| Q2 24 | $315.7M | $72.9M | ||
| Q1 24 | $331.4M | $69.2M |
| Q4 25 | $88.3M | $390.1M | ||
| Q3 25 | $73.7M | $383.9M | ||
| Q2 25 | $73.1M | $376.0M | ||
| Q1 25 | $53.2M | $366.1M | ||
| Q4 24 | $57.0M | $353.8M | ||
| Q3 24 | $92.9M | $327.6M | ||
| Q2 24 | $102.9M | $354.1M | ||
| Q1 24 | $144.0M | $382.0M |
| Q4 25 | $689.8M | $3.3B | ||
| Q3 25 | $669.3M | $3.2B | ||
| Q2 25 | $639.8M | $3.2B | ||
| Q1 25 | $596.7M | $3.2B | ||
| Q4 24 | $568.5M | $3.2B | ||
| Q3 24 | $561.5M | $3.3B | ||
| Q2 24 | $548.2M | $3.3B | ||
| Q1 24 | $545.7M | $3.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $413.4M |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 121.45× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $413.4M | ||
| Q3 25 | $1.0M | $99.0M | ||
| Q2 25 | $-32.4M | $104.5M | ||
| Q1 25 | $-43.4M | $101.0M | ||
| Q4 24 | $-26.2M | $393.5M | ||
| Q3 24 | $-18.6M | $108.5M | ||
| Q2 24 | $-30.1M | $107.7M | ||
| Q1 24 | $-53.5M | $85.9M |
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | — | ||
| Q1 24 | $-53.6M | — |
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — | ||
| Q1 24 | -71.4% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 121.45× | ||
| Q3 25 | — | 19.05× | ||
| Q2 25 | — | 15.20× | ||
| Q1 25 | — | 10.34× | ||
| Q4 24 | — | 45.04× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
